Aclidinium bromide/formoterol

From WikiProjectMed
Jump to navigation Jump to search
Aclidinium bromide/formoterol
Combination of
Aclidinium bromideLong-acting muscarinic antagonist
FormoterolLong-acting β2 agonist
Clinical data
Trade namesBrimica Genuair, Duaklir Genuair, Duaklir Pressair
AHFS/Drugs.comProfessional Drug Facts
License data
  • AU: B3
Routes of
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only) [1]
  • US: ℞-only [2]
  • EU: Rx-only [3][4]
  • In general: ℞ (Prescription only)
CAS Number

Aclidinium bromide/formoterol, sold under the brand names Duaklir and Brimica, is a fixed-dose combination medication for inhalation, used in the management of chronic obstructive pulmonary disease (COPD).[5] It consists of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol, a long-acting β2 agonist.[3][4]


  1. ^ "Duaklir Genuair 340 micrograms /12 micrograms inhalation powder - Summary of Product Characteristics (SmPC)". (emc). 9 September 2019. Retrieved 26 July 2020.
  2. ^ "Duaklir Pressair- aclidinium bromide and formoterol fumarte powder, metered". DailyMed. 3 July 2020. Retrieved 28 November 2020.
  3. ^ a b "Duaklir Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
  4. ^ a b "Brimica Genuair EPAR". European Medicines Agency (EMA). Retrieved 26 July 2020.
  5. ^ D'Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA (September 2021). "Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update". Expert Review of Respiratory Medicine. 15 (9): 1093–1106. doi:10.1080/17476348.2021.1920403. PMID 34137664.

External links